TP53 Deficiency in the Natural History of Prostate Cancer

Simple Summary Prostate cancer, one of the most prevalent malignancies in men worldwide, is associated with significant morbidity and mortality. Among the genetic alterations driving prostate cancer progression, mutations in TP53 play a pivotal role in tumor resistance to therapeutic interventions and the promotion of metastasis. This review examines the critical role of TP53 mutations in prostate cancer, emphasizing their contribution to disease progression and their influence on clinical outcomes. By synthesizing the current literature, we aim to underscore how a deeper understanding of the molecular underpinnings of prostate cancer, particularly its mutational landscape, can inform and enhance personalized treatment strategies. Furthermore, the review discusses emerging therapeutic approaches targeting TP53, offering potential avenues for novel treatments in patients with advanced disease.